Setmelanotide is a melanocortin-4-receptor agonist used for the treatment of hyperphagia in the genetic obesity syndrome Bardet-Biedl. Presented is a case of diffuse hyperpigmentation in a patient treated with setmelanotide, which represents the most common side effect of this medication. Herein is a review of the literature for other potential side effects that warrant regular dermatologic screening, including alteration of existing melanocytic lesions. Exact screening guidelines have not been completely defined, though it is recommended that patients receive baseline and annual examinations while undergoing treatment with this agent.
Keywords: Bardet‐Biedl syndrome, MCR4 agonist, melanoma risk, setmelanotide, skin cancer screening
Pediatric dermatology
Case Reports
English
41994885
Guideline Central and select third party use “cookies” on this website to enhance the user experience.
This technology helps us gather statistical and analytical information to optimize the relevant content for you.
The user also has the option to opt-out which may have an effect on the browsing experience.